Phase 3 studies of Direct Acting Antivirals(DAAs) in patients with chronic hepatitis C or cirrhosis included fewpatients over 70 years. To evaluate the safety and efficacy of DAAsin elderly, we used the ongoing dataset from our regional database, RESIST-HCV.
Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST-HCV, a large regional database
BERTINO, Gaetano;CACOPARDO, Bruno Santi;
2016-01-01
Abstract
Phase 3 studies of Direct Acting Antivirals(DAAs) in patients with chronic hepatitis C or cirrhosis included fewpatients over 70 years. To evaluate the safety and efficacy of DAAsin elderly, we used the ongoing dataset from our regional database, RESIST-HCV.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Treatment of elderly HCV patients with severe fibrosis.pdf
solo gestori archivio
Tipologia:
Versione Editoriale (PDF)
Dimensione
51.7 kB
Formato
Adobe PDF
|
51.7 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
